...
首页> 外文期刊>Trials >Intravenous morphine versus intravenous paracetamol after cardiac surgery in neonates and infants: a study protocol for a randomized controlled trial
【24h】

Intravenous morphine versus intravenous paracetamol after cardiac surgery in neonates and infants: a study protocol for a randomized controlled trial

机译:新生儿和婴儿心脏手术后静脉使用吗啡与静脉对乙酰氨基酚:一项随机对照试验的研究方案

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Morphine is worldwide the analgesic of first choice after cardiac surgery in children. Morphine has unwanted hemodynamic and respiratory side effects. Therefore, post–cardiac surgery patients may potentially benefit from a non-opioid drug for pain relief. A previous study has shown that intravenous (IV) paracetamol is effective and opioid-sparing in children after major non-cardiac surgery. The aim of the study is to test the hypothesis that intermittent IV paracetamol administration in children after cardiac surgery will result in a reduction of at least 30% of the cumulative morphine requirement. This is a prospective, multi-center, randomized controlled trial at four level-3 pediatric intensive care units (ICUs) in the Netherlands and Belgium. Children who are 0–36?months old will be randomly assigned to receive either intermittent IV paracetamol or continuous IV morphine up to 48?h post-operatively. Morphine will be available as rescue medication for both groups. Validated pain and sedation assessment tools will be used to monitor patients. The sample size (n?=?208, 104 per arm) was calculated in order to detect a 30% reduction in morphine dose; two-sided significance level was 5% and power was 95%. This study will focus on the reduction, or replacement, of morphine by IV paracetamol in children (0–36?months old) after cardiac surgery. The results of this study will form the basis of a new pain management algorithm and will be implemented at the participating ICUs, resulting in an evidence-based guideline on post-operative pain after cardiac surgery in infants who are 0–36?months old. Dutch Trial Registry ( www.trialregister.nl ): NTR5448 on September 1, 2015. Institutional review board approval (MEC2015–646), current protocol version: July 3, 2017
机译:吗啡是全世界儿童心脏手术后的首选镇痛药。吗啡具有不良的血液动力学和呼吸道副作用。因此,心脏外科手术后患者可能会受益于非阿片类药物缓解疼痛。先前的一项研究表明,对非心脏大手术后的儿童,静脉内(对乙酰氨基酚)对乙酰氨基酚有效且可减少阿片类药物的摄入。该研究的目的是检验以下假设,即在心脏手术后对儿童进行间歇性静脉内扑热息痛给药可减少至少30%的累积吗啡需求量。这是在荷兰和比利时的四个三级儿科重症监护病房(ICU)进行的一项前瞻性,多中心,随机对照试验。 0-36个月大的孩子将被随机分配接受间歇性静脉内扑热息痛或连续性吗啡吗啡治疗,直到术后48小时。吗啡可作为两组的急救药物。经过验证的疼痛和镇静评估工具将用于监视患者。计算样本量(n?=?208,每只手臂104个)以检测吗啡剂量减少30%。双面显着性水平为5%,功效为95%。这项研究的重点是在心脏手术后的儿童(0-36个月大)中通过静脉对乙酰氨基酚减少或替代吗啡。这项研究的结果将构成一种新的疼痛管理算法的基础,并将在参与的ICU实施,从而为循证指南制定了0-36个月大婴儿心脏手术后术后疼痛的指南。荷兰审判注册中心(www.trialregister.nl):2015年9月1日NTR5448。机构审查委员会批准(MEC2015–646),当前协议版本:2017年7月3日

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号